InflaRx is developing new anti-C5a medicines for inflammatory diseases. Credit: e-Magine Art.

InflaRx has completed patient enrolment in a Phase IIb clinical trial to evaluate IFX-1 in the treatment of moderate to severe hidradenitis suppurativa (HS).

HS is a chronic inflammatory skin disease that causes abscesses and scarring.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Investigational antibody IFX-1 is being developed to block the human complement factor C5a, an inflammatory mediator known to be associated with multiple autoimmune diseases.

The randomised, double-blind, placebo-controlled trial is designed to investigate the safety and efficacy of four different doses of IFX-1 over 16 weeks.

Primary endpoint of the trial is dose-response signal measured using the hidradenitis suppurativa clinical response (HiSCR) score at week 16.

“Our goal with this Phase IIb study is to determine the optimal dose regimen, as well as assess both long-term efficacy and safety of IFX-1.”

Conducted across 38 sites in North America and Europe, the study will also assess objectives such as the tolerability of IFX-1, additional efficacy and patient-reported outcome parameters.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The dosing period will be followed by a 28-week open-label extension phase to evaluate long-term efficacy and safety.

InflaRx chief medical officer Othmar Zenker said: “Following the promising results we observed in our earlier trial with IFX-1 in hidradenitis suppurativa, our goal with this Phase IIb study is to determine the optimal dose regimen, as well as assess both long-term efficacy and safety of IFX-1 in patients with this disease.”

So far, IFX-1 has been studied in three Phase II trials. In pre-clinical studies, the drug candidate displayed a capability to block C5a and control the tissue and organ damage caused by inflammatory response.

InflaRx expects to report top-line results from the Phase IIb trial in the first half of next year.